Evaxion Biotech Statistics
Total Valuation
EVAX has a market cap or net worth of $15.69 million. The enterprise value is $20.94 million.
| Market Cap | 15.69M |
| Enterprise Value | 20.94M |
Important Dates
The next estimated earnings date is Wednesday, May 29, 2024, before market open.
| Earnings Date | May 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
EVAX has 3.69 million shares outstanding.
| Shares Outstanding | 3.69M |
| Owned by Insiders (%) | 16.60% |
| Owned by Institutions (%) | 0.93% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 214.38 |
| Forward PS | 92.99 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 286.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18
| Current Ratio | 1.18 |
| Quick Ratio | 1.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.63 |
Financial Efficiency
Return on equity (ROE) is -1,238.10% and return on invested capital (ROIC) is -361.46%.
| Return on Equity (ROE) | -1,238.10% |
| Return on Assets (ROA) | -126.70% |
| Return on Capital (ROIC) | -361.46% |
| Revenue Per Employee | $1,490 |
| Profits Per Employee | -$451,531 |
| Employee Count | 49 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -790,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.77% in the last 52 weeks. The beta is -0.02, so EVAX's price volatility has been lower than the market average.
| Beta (1Y) | -0.02 |
| 52-Week Price Change | -72.77% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 7.37 |
| Relative Strength Index (RSI) | 62.88 |
| Average Volume (30 Days) | 691,733 |
Short Selling Information
| Short Interest | 42,584 |
| Short Previous Month | 43,017 |
| Short % of Shares Out | 1.18% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.23 |
Income Statement
In the last 12 months, EVAX had revenue of $73,000 and -$22.13 million in losses. Loss per share was -$8.10.
| Revenue | 73,000 |
| Gross Profit | 73,000 |
| Operating Income | -22.20M |
| Pretax Income | -22.92M |
| Net Income | -22.13M |
| EBITDA | -21.23M |
| EBIT | -21.23M |
| Loss Per Share | -$8.10 |
Balance Sheet
The company has $5.58 million in cash and $10.87 million in debt, giving a net cash position of -$5.29 million or -$1.43 per share.
| Cash & Cash Equivalents | 5.58M |
| Total Debt | 10.87M |
| Net Cash | -5.29M |
| Net Cash Per Share | -$1.43 |
| Equity / Book Value | -4.73M |
| Book Value Per Share | -1.28 |
| Working Capital | 1.27M |
Cash Flow
In the last 12 months, operating cash flow was -$17.69 million and capital expenditures -$87,000, giving a free cash flow of -$17.78 million.
| Operating Cash Flow | -17.69M |
| Capital Expenditures | -87,000 |
| Free Cash Flow | -17.78M |
| FCF Per Share | -$6.43 |
Margins
Gross margin is 100.00%, with operating and profit margins of -30,406.85% and -30,308.22%.
| Gross Margin | 100.00% |
| Operating Margin | -30,406.85% |
| Pretax Margin | -31,390.41% |
| Profit Margin | -30,308.22% |
| EBITDA Margin | -29,087.67% |
| EBIT Margin | -29,087.67% |
| FCF Margin | -24,353.42% |
Dividends & Yields
EVAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.12% |
| Shareholder Yield | -19.12% |
| Earnings Yield | -141.37% |
| FCF Yield | -113.60% |
Analyst Forecast
The average price target for EVAX is $11.00, which is 161.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 161.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 22, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 22, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
EVAX has an Altman Z-Score of -16.51 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.51 |
| Piotroski F-Score | 1 |